| CEO Name | Lars Fruergaard Jorgensen |
| Nationality | Denmark |
| Net Worth Estimation | $130 million |
Lars Fruergaard Jorgensen's estimated net worth of around $130 million is primarily attributed to his long-term executive roles and substantial stock ownership with Novo Nordisk A/S, as well as significant annual compensation, bonuses, and equity awards associated with his position as CEO. The valuation also reflects Novo Nordisk's strong financial performance and market capitalization growth, which impact the value of his equity holdings.
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S, has an estimated net worth of $130,000,000, which is 26% of the pharmaceutical sector's maximum CEO net worth of $500,000,000. His net worth is 13 times higher than the minimum estimated CEO net worth in this industry.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Lars Fruergaard Jorgensen Performance in Novo Nordisk A/S
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S, demonstrates transformational leadership driving innovation and sustainable growth in the pharmaceutical sector. His decision-making emphasizes strategic expansion in diabetes care and biopharmaceuticals, enhancing R&D efficiency and global market penetration. Under his leadership, Novo Nordisk has achieved significant performance gains, including revenue growth and increased shareholder value, solidifying its position as a leader in diabetes treatment worldwide.
Latest News
Novo Nordisk appoints Maziar Mike Doustdar as new CEO amid market challenges
Maziar Mike Doustdar became Novo Nordisk's president and CEO on August 7, 2025, succeeding Lars Fruergaard Jorgensen. His leadership aims to address competitive pressures in the weight-loss drug market, particularly in the U.S., while maintaining focus on growth in obesity and diabetes treatments.
Source: http://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916408